Intraurethral prostate injections with mepivacaine epinephrine: effects on patient comfort, treatment time and energy consumption during high-energy transurethral microwave thermotherapy.
Journal article, 2009
OBJECTIVE: To investigate the effects of intraprostatic mepivacaine epinephrine injections administered by the Schelin catheter during high-energy transurethral microwave thermotherapy (TUMT) using the CoreTherm Prostalund Feedback Treatment (PLFT) system. MATERIAL AND METHODS: The study included 85 men with lower urinary tract symptoms due to benign prostatic enlargement. One group had intraprostatic injections with mepivacaine epinephrine by the new Schelin catheter, while patients in the other group were treated without intraprostatic injections. All men were treated by TUMT using the PLFT system. Before treatment, transrectal ultrasound (TRUS) volume was measured. During the procedure, treatment time, energy consumption, cell-kill parameter and maximal prostate temperature were recorded. Patients who needed perioperative intravenous analgesics and the rate of perioperative and postoperative complications were registered. RESULTS: The patients who had intraprostatic and periprostatic injections with mepivacaine epinephrine had shorter effective treatment time and reduced energy consumption. There was also a difference between the two groups in that 70% of patients without intraprostatic injections and only 11% of injected patients needed intravenous analgesics. No differences were found in TRUS volume, estimated cell-kill, maximal prostate temperature or complication rates. CONCLUSIONS: Intraprostatic injections with mepivacaine epinephrine distributed by the Schelin catheter reduce the number of patients needing intravenous analgesics during PLFT, as well as the treatment time and energy consumption during treatment. Besides improved patient comfort, intraprostatic and periprostatic injections condense the treatment time without side-effects, making PLFT less cumbersome for most patients.
methods
Aged
Injections
Humans
surgery
Urologic Diseases
complications
therapeutic use
Prostatic Hyperplasia
administration & dosage
Time Factors
adverse effects
Treatment Outcome
Aged
Middle Aged
80 and over
Anesthetics
Pain
Transurethral Resection of Prostate
therapeutic use
etiology
Mepivacaine
prevention & control
Local
administration & dosage
Male
Author
Tomas Knutson
University of Gothenburg
Annika Johansson
University of Gothenburg
Jan-Erik Damber
University of Gothenburg
Magnus Fall
University of Gothenburg
Stepan Vesely
University of Gothenburg
Ralph Peeker
University of Gothenburg
Scandinavian Journal of Urology and Nephrology
0036-5599 (ISSN) 1651-2065 (eISSN)
Vol. 43 4 300-6Subject Categories
Urology and Nephrology
DOI
10.1080/00365590903092889
PubMed
19585385